Xvivo Perfusion ABXVIPF -1.32%91 Return-on-Tangible-Asset is 15.34% as of Mar. 2026, which is 450% above its 10-year median of 2.79. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 75.73% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Xvivo Perfusion AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $15.58 Mil. Xvivo Perfusion AB's average total tangible assets for the quarter that ended in Mar. 2026 was $101.59 Mil. Therefore, Xvivo Perfusion AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 15.34%.
The historical rank and industry rank for Xvivo Perfusion AB's Return-on-Tangible-Asset or its related term are showing as below:
XVIPF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -10.65 Med: 2.79 Max: 17.47
Current: 7.81
During the past 13 years, Xvivo Perfusion AB's highest Return-on-Tangible-Asset was 17.47%. The lowest was -10.65%. And the median was 2.79%.
XVIPF's Return-on-Tangible-Asset is ranked better than 75.73% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs XVIPF: 7.81
Xvivo Perfusion AB (OTCPK:XVIPF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Xvivo Perfusion AB Return-on-Tangible-Asset Related Terms
Xvivo Perfusion AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.34% mean?
Xvivo Perfusion AB (XVIPF) has a Return-on-Tangible-Asset of 15.34% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Xvivo Perfusion AB and its competitors. This is 450% above median its historical median of 2.79. According to the industry distribution chart, Xvivo Perfusion AB ranks #208 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 24.3%.
Is Xvivo Perfusion AB's Return-on-Tangible-Asset too high?
Xvivo Perfusion AB's current Return-on-Tangible-Asset of 15.34% is 450% above median its 10-year median of 2.79. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.71. Xvivo Perfusion AB's value of 15.34% is 2060.6% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #208 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #208 out of 857 companies for Return-on-Tangible-Asset. This places Xvivo Perfusion AB in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.71. Xvivo Perfusion AB's value of 15.34% is 2060.6% above this benchmark. While the company's 10-year median is 2.79 vs. the industry median of 0.71, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.71, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Return-on-Tangible-Asset of 15.34% is 2060.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Return-on-Tangible-Asset is 15.34%, which is 450% above median its own 10-year median of 2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Return-on-Tangible-Asset is 15.34%, which is 450% above median its 10-year median of 2.79 and 2060.6% above the Medical Devices & Instruments industry median of 0.71. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Return-on-Tangible-Asset is 15.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Return-on-Tangible-Asset: 15.34% (450% above median its 10-year median of 2.79)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 2060.6% above the Medical Devices & Instruments median (#208 of 857)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
